top of page
  • Recruiting

NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM

Updated: Sep 24, 2022

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

UCSD Health - University of Clifornia San Diego - Moores Cancer Center myeoma

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.


Sponsor


Collaborators

 

ClinicalTrials.gov Identifier: NCT03590652

Official Title: Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)

First Posted : July 18, 2018

Click here for details on ClinicalTrials.gov

 



 

Locations

United States, California

UCSD Health - University of Clifornia San Diego - Moores Cancer Center











Comments


Posts Archive
bottom of page